Type a word to start your search

Loading

Natural cosmeceutical with advanced antioxidant properties

The project aims to advance the production of an active antioxidant ingredient prototype for the cosmeceutical industry.
This acceleration phase focuses on implementing optimized extraction techniques and stabilization processes for the ingredient. Concurrently, rigorous quality tests will be conducted to ensure the ingredient meets industry standards in terms of purity, stability, and efficacy. This phase will not only refine the functional characteristics of the ingredient but also ensure its compatibility with various cosmetic formulations in which it might be incorporated.

The project also considers the entire production cycle of the active ingredient, emphasizing sustainability through the use of green chemistry processes and responsible resource management. This approach aims to minimize the product's environmental footprint and ensure full traceability, two critical aspects to address the growing demand for environmentally friendly and health-conscious cosmetic ingredients.

The ultimate goal of the project is to support the production of a batch of the ingredient for a validation study involving potential consumers. This study will gather valuable data, particularly through testimonials, about the ingredient's beneficial effects, such as its ability to improve the skin's overall appearance. These results will be essential in substantiating product claims during market introduction.

By collecting data on the ingredient's impact on human skin, the project will provide a foundation for successful commercialization while addressing regulatory challenges associated with bringing such a product to market. Once finalized, this ingredient will meet the increasing demand for innovative, natural-origin products with proven efficacy in skincare, particularly in protecting against premature aging and damage caused by free radicals—a highly competitive and rapidly growing market.

Marc-Antoine Goulet

Corporate Development Director
Premier Tech

CRIBIQ's contribution

$ 250 000


Partners

Industrial participants :

SCF Pharma, SEREX

QPRI*
*Quebec public research institutes :

Premier Tech inc.